Tarsus Pharmaceuticals plans to initiate a Phase 2 study for TP-04, targeting Ocular Rosacea treatment. ... a treatment for Demodex blepharitis, generating over $113 million in sales.

Lotilaner, 0.25%, complements our overall strategy for managing patients with facial rosacea, ocular rosacea, and meibomian gland dysfunction by addressing Demodex at the eyelash base and inside ...

Ocular Rosacea Trial Beyond DB, TARS is developing TP-04 a gel formulation of lotilaner for Ocular Rosacea, which TARS notes impacts about 15M-18M in the US, and 50% the time is caused by Demodex ...

Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned ...

Eye mites are also more common in people who wear contact lenses and people with rosacea, blepharitis or diabetes. Diagnosis and treatment Eye doctors can detect mites during an exam by inspecting ...

Eye mites are also more common in people who wear contact lenses and people with rosacea, blepharitis or diabetes. Diagnosis and treatment Eye doctors can detect mites during an exam by inspecting ...

Eye mites are also more common in people who wear contact lenses and people with rosacea, blepharitis or diabetes. Diagnosis and treatment Eye doctors can detect mites during an exam by inspecting ...

On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025 , at 1:30 p ...

Eye mites are also more common in people who wear contact lenses and people with rosacea, blepharitis or diabetes. Diagnosis and treatment Eye doctors can detect mites during an exam by inspecting ...